Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the overall effectiveness of Ondansetron as an
adjunctive or "add-on" medication in the treatment of Schizophrenia. This study is a double
blind, placebo-controlled, randomised, 12 week trial.